NEW
YORK, June 19, 2024 /PRNewswire/ -- The
global atopic dermatitis drugs market size is estimated
to grow by USD 6.20 billion from
2024-2028, according to Technavio. The market is estimated to grow
at a CAGR of 10.87% during the forecast
period. High prevalence of atopic dermatitis is
driving market growth, with a trend towards strategic
partnerships and acquisitions. However, side effects
associated with corticosteroids poses a challenge. Key market
players include AbbVie Inc., Arcutis Biotherapeutics Inc., Asana
BioSciences LLC, Astellas Pharma Inc., Bausch Health Companies
Inc., Bayer AG, BiomX Inc., Bristol Myers Squibb Co., Dermavant
Sciences Inc., Eli Lilly and Co., Evelo Biosciences Inc., Galderma
SA, Incyte Corp., LEO Pharma AS, Maruho Co. Ltd., Novartis AG,
Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, and Viatris
Inc..
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Route Of Administration
(Oral, Topical, and Injectable), Drug Class (Biologics, PDE4
inhibitors, Corticosteroids, and Calcineurin inhibitors), and
Geography (North America, Europe, Asia, and Rest of World
(ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
AbbVie Inc., Arcutis
Biotherapeutics Inc., Asana BioSciences LLC, Astellas Pharma Inc.,
Bausch Health Companies Inc., Bayer AG, BiomX Inc., Bristol Myers
Squibb Co., Dermavant Sciences Inc., Eli Lilly and Co., Evelo
Biosciences Inc., Galderma SA, Incyte Corp., LEO Pharma AS, Maruho
Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc.,
Sanofi SA, and Viatris Inc.
|
Key Market Trends Fueling Growth
Vendors in the global atopic dermatitis drugs market have
expanded their product offerings through strategic initiatives such
as mergers and acquisitions and technology collaborations since
2019. For instance, Pfizer and Glenmark's introduction of
Abrocitinib, an approved treatment for moderate-to-severe atopic
dermatitis, in India and other
regions, is a notable example. Such partnerships and approvals
contribute to market growth and potential profit margin
increases.
The Atopic Dermatitis Drugs Market is experiencing significant
growth due to the rising prevalence of atopic dermatitis worldwide.
The market consists of various treatments, including topical
corticosteroids, calcineurin inhibitors, and biologics. Topical
corticosteroids remain the first-line therapy for mild to moderate
atopic dermatitis. Calcineurin inhibitors are used for sensitive
areas and long-term treatment. Biologics, such as dupilumab, are
emerging as effective treatments for severe atopic dermatitis. The
market is also witnessing the development of new drugs, like PDE4
inhibitors and JAK inhibitors, which show promising results. The
regulatory approval of these new drugs is expected to further boost
the market growth. Additionally, the increasing awareness and
diagnosis of atopic dermatitis are driving the market
demand.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
• The atopic
dermatitis drugs market is challenged by the limited use of
corticosteroids due to their potential side effects. These
medications, including clobetasol propionate and fluocinonide,
effectively reduce itching, inflammation, and redness. However,
their long-term use is discouraged due to risks like skin thinning,
thickening, and discoloration. Systemic side effects, such as fluid
retention, high blood pressure, bone damage, and Cushings Syndrome,
further limit their adoption. Patients typically resort to
corticosteroids when other skincare regimens fail, but the market
growth is hindered by these constraints.
• The Atopic
Dermatitis Drugs Market faces several challenges in providing
effective treatments. Topical corticosteroids, such as Clobetasone
and Dexamethasone, are commonly used for their anti-inflammatory
properties. However, long-term use can lead to side effects like
thinning of the skin and increased risk of infections. Calcineurin
inhibitors, like Tacrolimus and Pimecrolimus, are alternative
options, but they can cause burning and itching at the application
site. Biologics, like Dupilumab and Eczema, offer promising results
but come with higher costs and potential safety concerns.
Regulating authorities require rigorous testing and safety measures
to ensure patient safety. In addition, patient compliance and
adherence to treatment plans remain significant challenges.
Overall, the Atopic Dermatitis Drugs Market requires continuous
innovation and research to address these challenges and provide
effective, safe, and affordable treatment options.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This atopic dermatitis drugs market report extensively covers
market segmentation by
- Route Of Administration
- 1.1 Oral
- 1.2 Topical
- 1.3 Injectable
- Drug Class
- 2.1 Biologics
- 2.2 PDE4 inhibitors
- 2.3 Corticosteroids
- 2.4 Calcineurin inhibitors
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Oral-
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2018 - 2022) - Download a Sample Report
Research Analysis
The Atopic Dermatitis Drugs Market encompasses a range of
treatments for this prevalent inflammatory skin condition.
Corticosteroids, including topical forms, have long been a mainstay
in managing symptoms. However, regulatory complexities and
healthcare access disparities have led to an increased interest in
novel treatments. Biologics and targeted therapies, such as
Ruxolitinib Cream, are emerging as effective alternatives. The
adoption of telemedicine in hospital pharmacies facilitates easier
access to these treatments for pediatric patients and adults alike.
The disease prevalence, driven by Westernized lifestyles,
contributes significantly to healthcare expenditure. Novel
products, like Crisaborole ointment, and hand eczema treatments are
also gaining traction. Infections and oil stripping soaps can
exacerbate Atopic Dermatitis, making the development of effective
treatments a priority.
Market Research Overview
The Atopic Dermatitis Drugs Market encompasses a range of
treatments for this chronic and relapsing inflammatory skin
condition. These drugs include topical corticosteroids, calcineurin
inhibitors, phototherapy, and biologics. Topical corticosteroids
are commonly used for mild to moderate atopic dermatitis, while
calcineurin inhibitors are preferred for sensitive areas or in
cases of steroid resistance. Phototherapy, including UVB and PUVA,
is effective for severe cases, but carries the risk of side
effects. Biologics, such as dupilumab, are the latest addition to
the market, offering a targeted approach to treating atopic
dermatitis by inhibiting specific cytokines involved in the
inflammatory response. The market for these drugs is expected to
grow due to the increasing prevalence of atopic dermatitis and the
development of new, more effective treatments.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Route Of Administration
-
- Drug Class
-
- Biologics
- PDE4 Inhibitors
- Corticosteroids
- Calcineurin Inhibitors
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/atopic-dermatitis-drugs-market-size-is-set-to-grow-by-usd-6-20-billion-from-2024-2028--high-prevalence-of-atopic-dermatitis-to-boost-the-market-growth-technavio-302175325.html
SOURCE Technavio